10x Genomics (NASDAQ:TXG – Free Report) – Leerink Partnrs upped their Q3 2025 earnings estimates for 10x Genomics in a note issued to investors on Monday, October 13th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.26) per share for the quarter, up from their prior estimate of ($0.28). The consensus estimate for 10x Genomics’ current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for 10x Genomics’ Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.90) EPS, Q1 2026 earnings at ($0.23) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.24) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.91) EPS and FY2027 earnings at ($0.57) EPS.
10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million for the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS.
Get Our Latest Research Report on 10x Genomics
10x Genomics Trading Up 3.0%
NASDAQ TXG opened at $11.89 on Thursday. The company’s 50-day moving average price is $12.89 and its 200-day moving average price is $11.10. The stock has a market cap of $1.48 billion, a PE ratio of -16.99 and a beta of 2.05. 10x Genomics has a 12 month low of $6.78 and a 12 month high of $18.21.
Institutional Trading of 10x Genomics
A number of institutional investors have recently modified their holdings of TXG. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of 10x Genomics by 235.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company’s stock valued at $62,016,000 after buying an additional 4,987,195 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of 10x Genomics by 434.5% in the 1st quarter. Millennium Management LLC now owns 5,377,492 shares of the company’s stock valued at $46,946,000 after buying an additional 4,371,327 shares in the last quarter. AQR Capital Management LLC boosted its holdings in shares of 10x Genomics by 241.3% in the 2nd quarter. AQR Capital Management LLC now owns 4,137,801 shares of the company’s stock valued at $47,916,000 after buying an additional 2,925,372 shares in the last quarter. Quantinno Capital Management LP boosted its holdings in shares of 10x Genomics by 207.2% in the 2nd quarter. Quantinno Capital Management LP now owns 2,233,526 shares of the company’s stock valued at $25,864,000 after buying an additional 1,506,530 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of 10x Genomics by 3,619.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,166,723 shares of the company’s stock valued at $10,185,000 after buying an additional 1,135,356 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors.
Insider Activity
In other news, CFO Adam Taich sold 22,315 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the sale, the chief financial officer directly owned 309,273 shares in the company, valued at approximately $4,264,874.67. This trade represents a 6.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the sale, the insider owned 440,888 shares in the company, valued at $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 39,149 shares of company stock worth $539,865. Corporate insiders own 9.39% of the company’s stock.
10x Genomics Company Profile
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Stories
- Five stocks we like better than 10x Genomics
- What is Put Option Volume?
- Palantir’s New Healthcare Deal Boosts AI and Data Reach
- How is Compound Interest Calculated?
- GM’s Billion-Dollar Bruise: GM’s Strategic Pivot Makes It a Buy
- Stock Splits, Do They Really Impact Investors?
- Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.